We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

Shares of Abbott Laboratories and Reckitt Benckiser fell Friday after a judge ruled a new trial could be heard involving a case on their infant formula products that had already seen a ruling in their ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Two former employees say the Scarborough plant failed to accommodate their disabilities and created a hostile work ...

Abbott Laboratories and Reckitt Benckiser Group Plc shares fell as a judge ordered a new trial after rejecting a verdict that ...

根据提交给证券交易委员会的文件显示，Abbott Laboratories（NYSE:ABT）执行副总裁Louis H. Morrone最近进行了一系列股票交易。3月3日，Morrone以每股138.17美元的价格出售了1,111股Abbott ...

a debilitating intestinal disease that can cause bloating, vomiting and diarrhea in premature babies. A previous ruling last July had found Abbott Labs failed to adequately warn of this risk.

Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary Mead Johnson not responsible for a ...

The ruling overturned a previous verdict related to an infant formula case and has implications for both Abbott and Reckitt, ...

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new ...

Abbott将在临床试验的多个方面提供支持，包括规划、试验点选择以及分享其HeartMate 3™的使用经验。在LVAD市场中，Abbott的HeartMate 3™是目前美国唯一可用的设备，该市场在2023年估值为USD 11亿，预计到2032年将达到USD 24亿。

Abbott (ABT) in October 2024 won the Whitfield case, though the plaintiffs appealed the Whitfield verdict and on Thursday, the judge granted a ...